according to Regulation (EC) No. 1907/2006



Mirtazapine Disintegrating Formulation

Version SDS Number: Date of last issue: 01.10.2020 Revision Date: 2.5 09.04.2021 51119-00017 Date of first issue: 23.01.2015

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier

Trade name Mirtazapine Disintegrating Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Sub-: Pharmaceutical

stance/Mixture

1.3 Details of the supplier of the safety data sheet

Company Organon & Co.

30 Hudson Street, 33nd floor

07302 Jersey City, New Jersey, U.S.A

Telephone 551-430-6000

E-mail address of person responsible for the SDS

EHSSTEWARD@organon.com

1.4 Emergency telephone number

215-631-6999

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Classification (REGULATION (EC) No 1272/2008)

Acute toxicity, Category 4 H302: Harmful if swallowed.

Reproductive toxicity, Category 2 H361fd: Suspected of damaging fertility. Suspected

of damaging the unborn child.

Specific target organ toxicity - repeated H373: May cause damage to organs through pro-

exposure, Category 2 longed or repeated exposure.

Long-term (chronic) aquatic hazard, Cat-H412: Harmful to aquatic life with long lasting ef-

egory 3 fects.

2.2 Label elements

Labelling (REGULATION (EC) No 1272/2008)

Hazard pictograms



Signal word Warning

H302 Harmful if swallowed. Hazard statements

H361fd Suspected of damaging fertility. Suspected of damag-

ing the unborn child.

H373 May cause damage to organs through prolonged or

repeated exposure.

according to Regulation (EC) No. 1907/2006



Mirtazapine Disintegrating Formulation

Version Revision Date: SDS Number: Date of last issue: 01.10.2020 2.5 09.04.2021 51119-00017 Date of first issue: 23.01.2015

H412 Harmful to aquatic life with long lasting effects.

Precautionary statements : Prevention:

P201 Obtain special instructions before use.

P260 Do not breathe dust.

P270 Do not eat, drink or smoke when using this product.

P273 Avoid release to the environment.

P280 Wear protective gloves/ protective clothing/ eye protec-

tion/ face protection.

Response:

P308 + P313 IF exposed or concerned: Get medical advice/

attention.

Hazardous components which must be listed on the label:

(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine

2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Dust contact with the eyes can lead to mechanical irritation.

Contact with dust can cause mechanical irritation or drying of the skin.

May form explosive dust-air mixture during processing, handling or other means.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

Components

Chemical name	CAS-No. EC-No. Index-No. Registration number	Classification	Concentration (% w/w)
(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine	85650-52-8 288-060-6	Acute Tox. 4; H302 Repr. 2; H361fd STOT RE 2; H373 (Nervous system) Aquatic Chronic 2; H411	>= 20 - < 25
Citric acid	77-92-9 201-069-1	Eye Irrit. 2; H319	>= 1 - < 10

For explanation of abbreviations see section 16.

according to Regulation (EC) No. 1907/2006



Mirtazapine Disintegrating Formulation

Version Revision Date: SDS Number: Date of last issue: 01.10.2020 2.5 09.04.2021 51119-00017 Date of first issue: 23.01.2015

SECTION 4: First aid measures

4.1 Description of first aid measures

General advice : In the case of accident or if you feel unwell, seek medical ad-

vice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

Protection of first-aiders : First Aid responders should pay attention to self-protection,

and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

If inhaled : If inhaled, remove to fresh air.

Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty

of water.

Remove contaminated clothing and shoes.

Get medical attention. Wash clothing before reuse.

Thoroughly clean shoes before reuse.

In case of eye contact : If in eyes, rinse well with water.

Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting.

Get medical attention.

Rinse mouth thoroughly with water.

Never give anything by mouth to an unconscious person.

4.2 Most important symptoms and effects, both acute and delayed

Risks : Harmful if swallowed.

Suspected of damaging fertility. Suspected of damaging the

unborn child.

May cause damage to organs through prolonged or repeated

exposure.

Contact with dust can cause mechanical irritation or drying of

the skin.

Dust contact with the eyes can lead to mechanical irritation.

4.3 Indication of any immediate medical attention and special treatment needed

Treatment : Treat symptomatically and supportively.

SECTION 5: Firefighting measures

5.1 Extinguishing media

Suitable extinguishing media : Water spray

according to Regulation (EC) No. 1907/2006



Mirtazapine Disintegrating Formulation

Version Revision Date: SDS Number: Date of last issue: 01.10.2020 2.5 09.04.2021 51119-00017 Date of first issue: 23.01.2015

Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical

Unsuitable extinguishing

media

None known.

5.2 Special hazards arising from the substance or mixture

Specific hazards during fire-

fighting

: Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a

potential dust explosion hazard.

Exposure to combustion products may be a hazard to health.

Hazardous combustion prod: :

ucts

Carbon oxides

Nitrogen oxides (NOx)

Metal oxides

5.3 Advice for firefighters

Special protective equipment :

for firefighters

In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment. Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

SO.

Evacuate area.

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions : Use personal protective equipment.

Follow safe handling advice (see section 7) and personal pro-

tective equipment recommendations (see section 8).

6.2 Environmental precautions

Environmental precautions : Avoid release to the environment.

Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

6.3 Methods and material for containment and cleaning up

Methods for cleaning up : Sweep up or vacuum up spillage and collect in suitable con-

tainer for disposal.

Avoid dispersal of dust in the air (i.e., clearing dust surfaces

with compressed air).

Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.

according to Regulation (EC) No. 1907/2006



Mirtazapine Disintegrating Formulation

Version Revision Date: SDS Number: Date of last issue: 01.10.2020 2.5 09.04.2021 51119-00017 Date of first issue: 23.01.2015

Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to deter-

mine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

Technical measures : Static electricity may accumulate and ignite suspended dust

causing an explosion.

Provide adequate precautions, such as electrical grounding

and bonding, or inert atmospheres.

Local/Total ventilation

Use only with adequate ventilation.

Advice on safe handling

Do not breathe dust. Do not swallow.

Avoid contact with eyes.

Avoid contact with eyes.

Avoid prolonged or repeated contact with skin.

Wash skin thoroughly after handling.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure as-

sessment

Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition.

Take precautionary measures against static discharges. Do not eat, drink or smoke when using this product.

Take care to prevent spills, waste and minimize release to the

environment.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye

flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contami-

nated clothing before re-use.

7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers

: Keep in properly labelled containers. Store locked up. Store in

accordance with the particular national regulations.

Advice on common storage : Do not store with the following product types:

Strong oxidizing agents

7.3 Specific end use(s)

Specific use(s) : No data available

according to Regulation (EC) No. 1907/2006



Mirtazapine Disintegrating Formulation

Version Revision Date: SDS Number: Date of last issue: 01.10.2020 2.5 09.04.2021 51119-00017 Date of first issue: 23.01.2015

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

Occupational Exposure Limits

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
(+/-)- 1,2,3,4,10,14b- Hexahydro-2- methylpyra- zino[2,1- a]pyrido[2,3- c][2]benzazepine	85650-52-8	TWA	25 μg/m3	Internal
		Wipe limit	250 μg/100 cm ²	Internal
Cellulose	9004-34-6	OELV - 8 hrs (TWA)	10 mg/m3	IE OEL
	Further information: Where no specific short-term exposure limit is listed, a figure three times the long-term exposure limit value should be used			
Magnesium stea- rate	557-04-0	OELV - 8 hrs (TWA)	10 mg/m3	IE OEL
	Further information: Where no specific short-term exposure limit is listed, a figure three times the long-term exposure limit value should be used			

Predicted No Effect Concentration (PNEC) according to Regulation (EC) No. 1907/2006:

Substance name	Environmental Compartment	Value
Citric acid	Fresh water	0.44 mg/l
	Marine water	0.044 mg/l
	Sewage treatment plant	1000 mg/l
	Fresh water sediment	34.6 mg/kg dry weight (d.w.)
	Marine sediment	3.46 mg/kg dry weight (d.w.)
	Soil	33.1 mg/kg dry weight (d.w.)

8.2 Exposure controls

Engineering measures

Ensure adequate ventilation, especially in confined areas.

Minimize workplace exposure concentrations.

Apply measures to prevent dust explosions.

Ensure that dust-handling systems (such as exhaust ducts, dust collectors, vessels, and processing equipment) are designed in a manner to prevent the escape of dust into the work area (i.e., there is no leakage from the equipment).

Personal protective equipment

Eye protection : Wear the following personal protective equipment:

Safety goggles

Equipment should conform to I.S. EN 166

Hand protection

according to Regulation (EC) No. 1907/2006



Mirtazapine Disintegrating Formulation

Version Revision Date: SDS Number: Date of last issue: 01.10.2020 2.5 09.04.2021 51119-00017 Date of first issue: 23.01.2015

Material : Chemical-resistant gloves

Remarks : Choose gloves to protect hands against chemicals depending

on the concentration and quantity of the hazardous substance and specific to place of work. Breakthrough time is not determined for the product. Change gloves often! For special applications, we recommend clarifying the resistance to chemicals of the aforementioned protective gloves with the glove manufacturer. Wash hands before breaks and at the

end of workday.

Skin and body protection : Select appropriate protective clothing based on chemical

resistance data and an assessment of the local exposure

potential.

Skin contact must be avoided by using impervious protective

clothing (gloves, aprons, boots, etc).

Respiratory protection : If adequate local exhaust ventilation is not available or expo-

sure assessment demonstrates exposures outside the rec-

ommended guidelines, use respiratory protection. Equipment should conform to I.S. EN 143

Filter type : Particulates type (P)

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Physical state : powder

Colour : No data available
Odour : No data available
Odour Threshold : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling

range

No data available

Flammability (solid, gas) : May form explosive dust-air mixture during processing, han-

dling or other means.

Flammability (liquids) : No data available

Upper explosion limit / Upper

flammability limit

No data available

Lower explosion limit / Lower

flammability limit

No data available

Flash point : No data available

Auto-ignition temperature : No data available

Decomposition temperature

Decomposition tempera: N

No data available

ture

pH : No data available

according to Regulation (EC) No. 1907/2006



Mirtazapine Disintegrating Formulation

Version Revision Date: SDS Number: Date of last issue: 01.10.2020 2.5 09.04.2021 51119-00017 Date of first issue: 23.01.2015

Viscosity

Viscosity, dynamic No data available

No data available Viscosity, kinematic

Solubility(ies)

No data available Water solubility

Partition coefficient: n-

octanol/water

No data available

No data available

No data available

Vapour pressure No data available

Density

Particle characteristics

Relative vapour density

No data available Particle size

9.2 Other information

Explosives Not explosive

Oxidizing properties The substance or mixture is not classified as oxidizing.

Evaporation rate No data available

No data available Molecular weight

SECTION 10: Stability and reactivity

10.1 Reactivity

Not classified as a reactivity hazard.

10.2 Chemical stability

Stable under normal conditions.

10.3 Possibility of hazardous reactions

Hazardous reactions May form explosive dust-air mixture during processing, han-

dling or other means.

Can react with strong oxidizing agents.

10.4 Conditions to avoid

Conditions to avoid Heat, flames and sparks.

Avoid dust formation.

10.5 Incompatible materials

Materials to avoid Oxidizing agents

10.6 Hazardous decomposition products

No hazardous decomposition products are known.

according to Regulation (EC) No. 1907/2006



Mirtazapine Disintegrating Formulation

Version Revision Date: SDS Number: Date of last issue: 01.10.2020 2.5 09.04.2021 51119-00017 Date of first issue: 23.01.2015

SECTION 11: Toxicological information

11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008

Information on likely routes of : Inhalation exposure Skin contact

Skin contact Ingestion Eye contact

Acute toxicity

Harmful if swallowed.

Product:

Acute oral toxicity : Acute toxicity estimate: 1,588 mg/kg

Method: Calculation method

Components:

(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:

Acute oral toxicity : LD50 (Rat): 320 - 490 mg/kg

Citric acid:

Acute oral toxicity : LD50 (Mouse): 5,400 mg/kg

Acute dermal toxicity : LD50 (Rat): > 2,000 mg/kg

Method: OECD Test Guideline 402

Assessment: The substance or mixture has no acute dermal

toxicity

Skin corrosion/irritation

Not classified based on available information.

Components:

Citric acid:

Species : Rabbit

Method : OECD Test Guideline 404

Result : No skin irritation

Serious eye damage/eye irritation

Not classified based on available information.

Components:

Citric acid:

Species : Rabbit

Method : OECD Test Guideline 405

Result : Irritation to eyes, reversing within 21 days

according to Regulation (EC) No. 1907/2006



Mirtazapine Disintegrating Formulation

Version Revision Date: SDS Number: Date of last issue: 01.10.2020 2.5 09.04.2021 51119-00017 Date of first issue: 23.01.2015

Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Germ cell mutagenicity

Not classified based on available information.

Components:

(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: In vitro mammalian cell gene mutation test

Test system: Chinese hamster lung cells

Result: negative

Test Type: unscheduled DNA synthesis assay

Test system: mammalian cells

Result: negative

Test Type: sister chromatid exchange assay

Test system: mammalian cells

Result: negative

Genotoxicity in vivo : Test Type: Micronucleus test

Species: Rat

Cell type: Bone marrow Application Route: Oral Result: negative

Citric acid:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: in vitro micronucleus test

Result: positive

Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Genotoxicity in vivo : Test Type: Mutagenicity (in vivo mammalian bone-marrow

cytogenetic test, chromosomal analysis)

Species: Rat

Application Route: Ingestion

Result: negative

Carcinogenicity

Not classified based on available information.

according to Regulation (EC) No. 1907/2006



Mirtazapine Disintegrating Formulation

Version Revision Date: SDS Number: Date of last issue: 01.10.2020 2.5 09.04.2021 51119-00017 Date of first issue: 23.01.2015

Components:

(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:

Species : Mouse Application Route : Oral

Exposure time : 18 month(s)

LOAEL : 200 mg/kg body weight

Result : equivocal Target Organs : Liver

Species : Rat
Application Route : Oral
Exposure time : 2 Years

LOAEL : 20 mg/kg body weight

Result : equivocal Target Organs : Liver, Thyroid

Reproductive toxicity

Suspected of damaging fertility. Suspected of damaging the unborn child.

Components:

(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:

Effects on fertility : Test Type: Fertility/early embryonic development

Species: Rat

Application Route: Oral

Fertility: LOAEL: 15 mg/kg body weight

Symptoms: Effect on estrous cycle, Increase of early resorp-

tions

Result: Animal testing did not show any effects on fertility., Embryotoxic effects and adverse effects on the offspring were

detected.

Effects on foetal develop-

ment

Test Type: Development

Species: Rat

Application Route: Oral

Developmental Toxicity: LOAEL: 100 mg/kg body weight Result: Embryotoxic effects and adverse effects on the off-

spring were detected., No teratogenic effects

Test Type: Development

Species: Rabbit Application Route: Oral

Developmental Toxicity: NOAEL: 40 mg/kg body weight Result: No adverse effects, No teratogenic effects

Reproductive toxicity - As-

sessment

Some evidence of adverse effects on sexual function and fertility, based on animal experiments.. Some evidence of

adverse effects on development, based on animal experi-

ments.

Citric acid:

Effects on foetal develop- : Test Type: One-generation reproduction toxicity study

according to Regulation (EC) No. 1907/2006



Mirtazapine Disintegrating Formulation

Version Revision Date: SDS Number: Date of last issue: 01.10.2020 2.5 09.04.2021 51119-00017 Date of first issue: 23.01.2015

ment Species: Rat

Application Route: Ingestion

Result: negative

STOT - single exposure

Not classified based on available information.

STOT - repeated exposure

May cause damage to organs through prolonged or repeated exposure.

Components:

(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:

Exposure routes : Ingestion

Target Organs : Nervous system

Assessment : May cause damage to organs through prolonged or repeated

exposure.

Repeated dose toxicity

Components:

(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:

Species : Rat

LOAEL : 120 mg/kg
Application Route : Oral
Exposure time : 13 Weeks
Target Organs : Nervous system

Species : Dog
LOAEL : 15 mg/kg
Application Route : Oral
Exposure time : 52 Weeks
Target Organs : Nervous system

Symptoms : Tremors

Species : Dog LOAEL : 20 mg/kg Application Route : Oral Exposure time : 13 Weeks

Target Organs : Nervous system, Testis

Symptoms : Tremors

Citric acid:

Species : Rat

NOAEL : 4,000 mg/kg
LOAEL : 8,000 mg/kg
Application Route : Ingestion
Exposure time : 10 Days

Aspiration toxicity

Not classified based on available information.

according to Regulation (EC) No. 1907/2006



Mirtazapine Disintegrating Formulation

Version Revision Date: SDS Number: Date of last issue: 01.10.2020 2.5 09.04.2021 51119-00017 Date of first issue: 23.01.2015

11.2 Information on other hazards

Endocrine disrupting properties

Product:

Assessment : The substance/mixture does not contain components consid-

ered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at

levels of 0.1% or higher.

Experience with human exposure

Components:

(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:

Ingestion : Symptoms: Drowsiness, constipation, dry mouth, asthenia,

Dizziness, Disorientation

SECTION 12: Ecological information

12.1 Toxicity

Components:

(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): 6.92 mg/l

Exposure time: 96 h Method: FDA 4.11

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): 19.5 mg/l

Exposure time: 48 h

Toxicity to algae/aquatic

plants

EC50 (Pseudokirchneriella subcapitata (green algae)): 5.7

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 3.2

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

Toxicity to microorganisms : EC50 (Natural microorganism): > 1,000 mg/l

Exposure time: 3 h

Test Type: Respiration inhibition Method: OECD Test Guideline 209

NOEC (Natural microorganism): < 100 mg/l

Exposure time: 3 h

Test Type: Respiration inhibition Method: OECD Test Guideline 209

Toxicity to fish (Chronic tox- : NOEC: 3.6 mg/l

according to Regulation (EC) No. 1907/2006



Mirtazapine Disintegrating Formulation

Version Revision Date: SDS Number: Date of last issue: 01.10.2020 2.5 09.04.2021 51119-00017 Date of first issue: 23.01.2015

icity) Exposure time: 31 d

Species: Pimephales promelas (fathead minnow)

Method: OECD Test Guideline 210

Toxicity to daphnia and other : aquatic invertebrates (Chron-

NOEC: 0.32 mg/l Exposure time: 21 d

ic toxicity)

Species: Daphnia magna (Water flea) Method: OECD Test Guideline 211

Citric acid:

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): > 100 mg/l

Exposure time: 96 h

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): 1,535 mg/l

Exposure time: 24 h

12.2 Persistence and degradability

Components:

Citric acid:

Biodegradability : Result: Readily biodegradable.

Biodegradation: 97 % Exposure time: 28 d

Method: OECD Test Guideline 301B

12.3 Bioaccumulative potential

Components:

(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:

Bioaccumulation : Species: Oncorhynchus mykiss (rainbow trout)

Bioconcentration factor (BCF): 334 Method: OECD Test Guideline 305

Partition coefficient: n-

octanol/water

log Pow: 2.78

Citric acid:

Partition coefficient: n-

octanol/water

log Pow: -1.72

12.4 Mobility in soil

Components:

(+/-)-1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine:

Distribution among environ-

mental compartments

: log Koc: 4.48

12.5 Results of PBT and vPvB assessment

Product:

Assessment : This substance/mixture contains no components considered

according to Regulation (EC) No. 1907/2006



Mirtazapine Disintegrating Formulation

Version Revision Date: SDS Number: Date of last issue: 01.10.2020 2.5 09.04.2021 51119-00017 Date of first issue: 23.01.2015

to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of

0.1% or higher.

12.6 Endocrine disrupting properties

Product:

Assessment : The substance/mixture does not contain components consid-

ered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at

levels of 0.1% or higher.

12.7 Other adverse effects

No data available

SECTION 13: Disposal considerations

13.1 Waste treatment methods

Product : Dispose of in accordance with local regulations.

According to the European Waste Catalogue, Waste Codes

are not product specific, but application specific.

Waste codes should be assigned by the user, preferably in

discussion with the waste disposal authorities.

Contaminated packaging : Empty containers should be taken to an approved waste han-

dling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

SECTION 14: Transport information

14.1 UN number or ID number

Not regulated as a dangerous good

14.2 UN proper shipping name

Not regulated as a dangerous good

14.3 Transport hazard class(es)

Not regulated as a dangerous good

14.4 Packing group

Not regulated as a dangerous good

14.5 Environmental hazards

Not regulated as a dangerous good

14.6 Special precautions for user

Not applicable

14.7 Maritime transport in bulk according to IMO instruments

Remarks : Not applicable for product as supplied.

according to Regulation (EC) No. 1907/2006



Mirtazapine Disintegrating Formulation

Version Revision Date: SDS Number: Date of last issue: 01.10.2020 2.5 09.04.2021 51119-00017 Date of first issue: 23.01.2015

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing on : Not applicable

the market and use of certain dangerous substances,

preparations and articles (Annex XVII)

REACH - Candidate List of Substances of Very High : Not applicable

Concern for Authorisation (Article 59).

REACH - List of substances subject to authorisation : Not applicable

(Annex XIV)

Regulation (EC) No 1005/2009 on substances that de- : Not applicable

plete the ozone layer

Regulation (EU) 2019/1021 on persistent organic pollu- : Not applicable

tants (recast)

Regulation (EC) No 649/2012 of the European Parlia: Not applicable

ment and the Council concerning the export and import

of dangerous chemicals

Seveso III: Directive 2012/18/EU of the European Parliament and of the Council on the control of major-accident hazards involving dangerous substances.

Not applicable

Other regulations:

Take note of Directive 92/85/EEC regarding maternity protection or stricter national regulations, where applicable.

Take note of Directive 94/33/EC on the protection of young people at work or stricter national regulations, where applicable.

The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

Other information : Items where changes have been made to the previous version

are highlighted in the body of this document by two vertical

lines.

Full text of H-Statements

H302 : Harmful if swallowed.

H319 : Causes serious eye irritation.

H361fd : Suspected of damaging fertility. Suspected of damaging the

unborn child.

H373 : May cause damage to organs through prolonged or repeated

exposure if swallowed.

H411 : Toxic to aquatic life with long lasting effects.

according to Regulation (EC) No. 1907/2006



Mirtazapine Disintegrating Formulation

Version Revision Date: SDS Number: Date of last issue: 01.10.2020 2.5 09.04.2021 51119-00017 Date of first issue: 23.01.2015

Full text of other abbreviations

Acute Tox. : Acute toxicity

Aquatic Chronic : Long-term (chronic) aquatic hazard

Eye Irrit. : Eye irritation

Repr. : Reproductive toxicity

STOT RE : Specific target organ toxicity - repeated exposure

IE OEL : Ireland. List of Chemical Agents and Occupational Exposure

Limit Values - Schedule 1

IE OEL / OELV - 8 hrs (TWA) : Occupational exposure limit value (8-hour reference period)

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - European Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN -Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS -Emergency Schedule: ENCS - Existing and New Chemical Substances (Japan): ErCx - Concentration associated with x% growth rate response: GHS - Globally Harmonized System: GLP -Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL -International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of Very High Concern; TCSI - Taiwan Chemical Substance Inventory; TRGS -Technical Rule for Hazardous Substances; TSCA - Toxic Substances Control Act (United States); UN - United Nations; vPvB - Very Persistent and Very Bioaccumulative

Further information

Sources of key data used to compile the Safety Data

Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen-

Sheet cy, http://echa.europa.eu/

Classification of the mixture:

Calculation method Calculation method

Calculation method

Classification procedure:

Acute Tox. 4 H302

Repr. 2 H361fd

STOT RE 2 H373

according to Regulation (EC) No. 1907/2006



Mirtazapine Disintegrating Formulation

Version Revision Date: SDS Number: Date of last issue: 01.10.2020 2.5 09.04.2021 51119-00017 Date of first issue: 23.01.2015

Aquatic Chronic 3 H412 Calculation method

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

IE / EN